Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Journal of the Korean Society of Pediatric Nephrology ; : 23-29, 2008.
Article Dans Coréen | WPRIM | ID: wpr-193240

Résumé

Kidney allograft transplantation is the most effective method of renal replacement for end stage renal disease patients. Still, it is another kind of 'disease', requiring immunosuppression to keep the allograft from rejection(allograft immune reaction). Immune system of the allograft recipient recognizes the graft as a 'pathogen(foreign or danger)', and the allograft-recognizing commander- in-chief of adaptive immune system, T cell, recruits all the components of immune system for attacking the graft. Proper activation and proliferation of T cell require signals from recognizing proper epitope(processed antigen by antigen presenting cell) via T cell receptor, costimulatory stimuli, and cytokines(IL-2). Thus, most of the immunosuppressive agents suppress the process of T cell activation and proliferation.


Sujets)
Humains , Système immunitaire , Immunosuppression thérapeutique , Immunosuppresseurs , Rein , Défaillance rénale chronique , Récepteurs aux antigènes des cellules T , , Tolérance à la transplantation , Transplantation homologue , Transplants
2.
Journal of the Korean Society of Pediatric Nephrology ; : 133-142, 2008.
Article Dans Coréen | WPRIM | ID: wpr-225439

Résumé

For solid organ transplant, ABO blood type of donor and recipient should be compatible in principle. Recent improvement of immunosuppressant made HLA typing not so important while no-mismatch transplant still shows the longest graft survival. PRA(panel reactive antibody) test is to screen and identify recipients with HLA sensitization. When solid organ transplant is scheduled, cross-match test of donor cell and recipient serum should be performed and positive result of cross-match prohibits transplantation. Donor specific antibody (DSA) test can predict the severity of recipient immune reaction against donor organ. Today's mainstay of allograft immunosuppressant regimen is triple therapy of steroid, calcineurin inhibitor(cyclosporine, tacrolimus), azathioprine or mycophenolate mofetil(MMF). Antibody induction using Thymoglobulin or anti-IL-2 receptor antibody(basiliximab or daclizumab) is frequently practiced as well.


Sujets)
Humains , Sérum antilymphocyte , Azathioprine , Calcineurine , Survie du greffon , Test d'histocompatibilité , Immunosuppression thérapeutique , Rein , Transplantation rénale , Donneurs de tissus , Transplantation homologue , Transplants
SÉLECTION CITATIONS
Détails de la recherche